EISAI CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,240 JPY | -0.30% |
|
+5.74% | -11.51% |
| 04-24 | Biogen beats quarterly profit estimates, Alzheimer's drug sales jump | RE |
| 04-23 | Alzheimer's drug adoption in US slowed by doctors' skepticism | RE |
| Sales 2024 * | 735B 4.64B 372B | Sales 2025 * | 778B 4.91B 393B | Capitalization | 1,790B 11.3B 905B |
|---|---|---|---|---|---|
| Net income 2024 * | 41.04B 259M 20.75B | Net income 2025 * | 49.92B 315M 25.24B | EV / Sales 2024 * | 2.2 x |
| Net cash position 2024 * | 172B 1.09B 87.12B | Net cash position 2025 * | 184B 1.16B 92.91B | EV / Sales 2025 * | 2.06 x |
| P/E ratio 2024 * |
43.8
x | P/E ratio 2025 * |
36
x | Employees | 11,076 |
| Yield 2024 * |
2.6% | Yield 2025 * |
2.66% | Free-Float | 93.84% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eisai Co., Ltd.
More recommendations
More press releases
| 1 day | -0.30% | ||
| 1 week | +5.74% | ||
| Current month | +0.39% | ||
| 1 month | -1.81% | ||
| 3 months | -10.28% | ||
| 6 months | -23.34% | ||
| Current year | -11.51% |
1 week
5 923.00
6 333.00
1 month
5 795.006 350.00
Current year
5 795.007 818.00
1 year
5 795.0011 250.00
3 years
5 011.0012 765.00
5 years
5 011.0012 765.00
10 years
3 900.0012 765.00
| Managers | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 01/10/75 |
Mitsuru Shomon
DFI | Director of Finance/CFO | - | - |
Makoto Hoketsu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 01/10/75 |
Fumihiko Ike
BRD | Director/Board Member | 71 | 31/05/21 |
Toru Moriyama
BRD | Director/Board Member | 69 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.78% | 15 M€ | +7.34% | ||
| 1.23% | 251 M€ | +13.17% | ||
| 1.13% | 31,732 M€ | +14.31% | - | |
| 1.12% | 1,198 M€ | +13.48% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 6,240 | -0.30% | 1,179,200 |
| 25/04/24 | 6,259 | +2.79% | 2,587,700 |
| 24/04/24 | 6,089 | -0.02% | 1,168,700 |
| 23/04/24 | 6,090 | -0.03% | 641,600 |
| 22/04/24 | 6,092 | +3.24% | 1,002,400 |
Delayed Quote Japan Exchange, April 26, 2024 at 07:00 am
More quotes
Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (87.7%): prescribed drugs, health products, etc.;
- other (12.3%): food additives, chemical products, etc.
Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).
Sector
Pharmaceuticals
Calendar
14/05/2024
- Q4 2023 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
6,240
JPY
Average target price
8,193
JPY
Spread / Average Target
+31.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.51% | 11.37B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4523 Stock
